Annual report pursuant to Section 13 and 15(d)

Statements of Stockholders’ Equity

v3.7.0.1
Statements of Stockholders’ Equity - USD ($)
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Subscriptions Receivable [Member]
Accumulated Loss [Member]
Beginning Balance at Jul. 27, 2015
Beginning Balance (in shares) at Jul. 27, 2015      
Stock issued for cash and subscription receivable $ 1,600 $ 4,600   (3,000)  
Stock issued for cash and subscription receivable (in Shares)   4,600,000      
Stock issued for licenses 2,061 $ 2,061      
Stock issued for licenses (in shares)   2,061,000      
Net loss (748,360)       (748,360)
Ending Balances at Dec. 31, 2015 (744,699) $ 6,661 0 (3,000) (748,360)
Endind Balances (in shares) at Dec. 31, 2015   6,661,000      
Private issuance @ $3.00 / share 702,894 $ 234 702,660    
Private issuance @ $3.00 / share (in shares)   234,297      
Issued for Moleculin acquisition 5,999,586 $ 1,000 5,998,586    
Issued for Moleculin acquisition (in shares)   999,931      
Issued for technology 3,774,000 $ 629 3,773,371    
Issued for technology (in shares)   629,000      
Issued for cash - IPO, net of stock issuance costs of $1,150,736 8,089,420 $ 1,540 8,087,880    
Issued for cash - IPO, net of stock issuance costs of $1,150,736 (in shares)   1,540,026      
Warrants issued for services 374,763   374,763    
Stock granted for services 157,680 $ 24 157,656    
Stock granted for services (in shares)   24,000      
Stock option expense 166,294   166,294    
Issued for convertible debt 363,792 $ 2,077 361,715    
Issued for convertible debt (in shares)   2,076,598      
Subscription agreement settled for cash 3,000     3,000  
Net loss (3,926,361)       (3,926,361)
Ending Balances at Dec. 31, 2016 $ 14,960,369 $ 12,165 $ 19,622,925 $ 0 $ (4,674,721)
Endind Balances (in shares) at Dec. 31, 2016   12,164,852